Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: An analysis of 100 cases

Oncology

Volumn 79, Issue 1-2, 2010, Pages 39-45

  Suzuki, Eiichiro ^a,b   Furuse, Junji ^b   Ikeda, Masafumi ^a   Okusaka, Takuji ^c   Nakachi, Kohei ^a   Mitsunaga, Shuichi ^a   Ueno, Hideki ^c   Morizane, Chigusa ^c   Kondo, Shunsuke ^c   Shimizu, Satoshi ^a   Kojima, Yasushi ^c   Hagihara, Atsushi ^c  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Biliary tract cancer; Gemcitabine; Monotherapy; Prognostic factors; Treatment efficacy; Treatment safety

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; GEMCITABINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIARY TRACT CANCER; BILIARY TRACT INFECTION; CANCER SURVIVAL; COGNITIVE DEFECT; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; HYPONATREMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIMETABOLITES, ANTINEOPLASTIC; BILIARY TRACT NEOPLASMS; C-REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SERUM ALBUMIN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78049458540     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000318020     Document Type: Article

References (33)

1. National Cancer Center. Cancer statistics in Japan 2007.http://www.fpcr. or.jp/publication/ statistics.html (accessed December 26, 2009).
2. Hezel AF, Zhu AX: Systemic therapy for biliary tract cancers. Oncologist 2008; 13: 415-423.
3. Yonemoto N, Furuse J, Okusaka T, Yamao K, Funakoshi A, Ohkawa S, Boku N, Tanaka K, Nagase M, Saisho H, Sato T: A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol 2007; 37: 843-851.
4. Eckel F, Schmid RM: Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007; 96: 896-902.
5. Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, Baka S, Maraveyas A, Corrie P, Falk S, Gollins S, Lofts F, Evans L, Meyer T, Anthoney A, Iveson T, Highley M, Osborne R, Bridgewater J: Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer 2009; 101: 621-627.
6. Valle JW, Wasan H, Palmer DD, Cunningham D, Anthoney A, Maraveyas A, Hughes SK, Roughton M, Bridgewater J: Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): results of a multicenter, randomized phase III trial (the UK ABC-02 trial). ASCO Annu Meet Proc 2009; 27:abstr 4503.
7. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
8. Todoroki T, Takahashi H, Koike N, Kawamoto T, Kondo T, Yoshida S, Kashiwagi H, Otsuka M, Fukao K, Saida Y: Outcomes of aggressive treatment of stage IV gallbladder cancer and predictors of survival. Hepatogastroenterology 1999; 46: 2114-2121.
9. Backes BG, Hauptmann S, Bocking A: Carcinoma of the extrahepatic biliary system: correlation of clinical, pathological, histological and DNA-cytometric parameters with prognosis. Anticancer Res 2000; 20: 1163-1168.
10. Saisho T, Okusaka T, Ueno H, Morizane C, Okada S: Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy. Hepatogastroenterology 2005; 52: 1654-1658.
11. Park I, Lee JL, Ryu MH, Kim TW, Sook Lee S, Hyun Park D, Soo Lee S, Wan Seo D, Koo Lee S, Kim MH: Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving firstline palliative chemotherapy. Cancer 2009; 115: 4148-4155.
12. Raderer M, Hejna MH, Valencak JB, Kornek GV, Weinländer GS, Bareck E, Lenauer J, Brodowicz T, Lang F, Scheithauer W: Two consecutive phase II studies of 5-fluorouracil/ leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology 1999; 56: 177-180.
13. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Lenauer A, Depisch D, Krauss G, Schneeweiss B, Scheithauer W: Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 2001; 12: 183-186.
14. Gallardo JO, Rubio B, Fodor M, Orlandi L, Yáñez M, Gamargo C, Ahumada M: A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 2001; 12: 1403-1406.
15. Lin MH, Chen JS, Chen HH, Su WC: A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas. Chemotherapy 2003; 49: 154-158.
16. Tsavaris N, Kosmas C, Gouveris P, Gennatas K, Polyzos A, Mouratidou D, Tsipras H, Margaris H, Papastratis G, Tzima E, Papadoniou N, Karatzas G, Papalambros E: Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs 2004; 22: 193-198.
17. Eng C, Ramanathan RK, Wong MK, Remick SC, Dai L, Wade-Oliver KT, Mani S, Kindler HL: A phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol 2004; 27: 565-569.
18. Park JS, Oh SY, Kim SH, Kwon HC, Kim JS, Jin-Kim H, Kim YH: Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Jpn J Clin Oncol 2005; 35: 68-73.
19. von Delius S, Lersch C, Schulte-Frohlinde E, Mayr M, Schmid RM, Eckel F: Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. BMC Cancer 2005; 5: 61.
20. Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, Saito H, Tsuyuguchi T: Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2006; 57: 647-653.
21. Al-Shaiba R, McMillan DC, Angerson WJ, Leen E, McArdle CS, Horgan P: The relationship between hypoalbuminaemia, tumour volume and the systemic inflammatory response in patients with colorectal liver metastases. Br J Cancer 2004; 91: 205-207.
22. McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, McArdle CS: Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 2001; 41: 64-69.
23. Barreto-Andrade JC, Medina-Franco H: Serum albumin is an independent prognostic factor for survival in soft tissue sarcomas. Rev Invest Clin 2009; 61: 198-204.
24. Kushner I: The phenomenon of the acute phase response. Ann NY Acad Sci 1982; 389: 39-48.
25. Geiger T, Andus T, Klapproth J, Hirano T, Kishimoto T, Heinrich PC: Induction of rat acute-phase proteins by interleukin 6 in vivo. Eur J Immunol 1988; 18: 717-721.
26. Strassmann G, Fong M, Kenney JS, Jacob CO: Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 1992; 89: 1681-1684.
27. Catalano V, Graziano F, Santini D, D'Emidio S, Baldelli AM, Rossi D, Vincenzi B, Giordani P, Alessandroni P, Testa E, Tonini G, Catalano G: Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Cancer 2008; 99: 1402-1407.
28. Watanabe K, Nagai K, Kobayashi A, Sugito M, Saito N: Factors influencing survival after complete resection of pulmonary metastases from colorectal cancer. Br J Surg 2009; 96: 1058-1065.
29. Huang O, Chen C, Wu J, Chen S, Chen X, Liu G, Hu Z, Lu J, Wu J, Shao Z, Shen Z, Shen K: Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months. BMC Cancer 2009; 9: 375.
30. Okamoto T, Nakamura T, Ikeda J, Maruyama R, Shoji F, Miyake T, Wataya H, Ichinose Y: Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer. Eur J Cancer 2005; 41: 1286-1290.
31. Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, Nematollahi M, Pond GR, Zhang J, Moore MJ: Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005; 23: 2332-2338.
32. Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, Selle F, Paye F, Hannoun L, Houry S, Gayet B, Lotz JP, de Gramont A, Louvet C: Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004; 15: 1339-1343.
33. Furuse J, Okusaka T, Ohkawa S, Nagase M, Funakoshi A, Boku N, Yamao K, Yamaguchi T, Sato T: A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer. Cancer Chemother Pharmacol 2009; 65: 113-120.